 Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company with research specialization in chronic hepatitis B virus HBV. In December 2021, ABUS reported its victory in the patent dispute over Moderna, involving its licensed four-lipid nanoparticles delivery system. 